Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Aralık 2024 | 0 |
| Ocak 2025 | 0 |
| Şubat 2025 | 0 |
| Mart 2025 | 0 |
| Nisan 2025 | 0 |
| Mayıs 2025 | 0 |
| Haziran 2025 | 0 |
